Cargando…

Editorial: Non-reactogenic vaccines against Q-fever

Detalles Bibliográficos
Autores principales:	Gregory, Anthony E., Davies, D. Huw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196460/ https://www.ncbi.nlm.nih.gov/pubmed/37215096 http://dx.doi.org/10.3389/fimmu.2023.1196522

Ejemplares similares

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses
por: Fratzke, Alycia P., et al.
Publicado: (2021)

Standardized guinea pig model for Q fever vaccine reactogenicity
por: Baeten, Laurie A., et al.
Publicado: (2018)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations
por: Niyomnaitham, Suvimol, et al.
Publicado: (2023)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge
por: Jan, Sharon, et al.
Publicado: (2023)

Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts
por: Gonzalez Dias Carvalho, Patrícia Conceição, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency
por: Göschl, Lisa, et al.
Publicado: (2022)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach
por: Williams, Erin C., et al.
Publicado: (2023)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

The Feasibility of Using Coxiella burnetii Avirulent Nine Mile Phase II Viable Bacteria as a Live Attenuated Vaccine Against Q fever
por: Kumaresan, Venkatesh, et al.
Publicado: (2021)

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity
por: Sato-Kaneko, Fumi, et al.
Publicado: (2020)

Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

Editorial: Nanoparticle Vaccines Against Infectious Diseases
por: Reljic, Rajko, et al.
Publicado: (2019)

Engineering Protein Nanoparticles Functionalized with an Immunodominant Coxiella burnetii Antigen to Generate a Q Fever Vaccine
por: Ramirez, Aaron, et al.
Publicado: (2023)

Editorial: Reassessing Twenty Years of Vaccine Development against Tuberculosis
por: Schaible, Ulrich E., et al.
Publicado: (2018)

Murine Q Fever Vaccination Model Reveals Sex Dimorphism in Early Phase Delayed-Type Hypersensitivity Responses
por: Binette, Picabo, et al.
Publicado: (2022)

Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity
por: Sluder, Ann E., et al.
Publicado: (2022)

Editorial: Recent advances in the development of vaccines against Acinetobacter baumannii
por: Khalili, Saeed, et al.
Publicado: (2023)

Editorial: Innovative Therapeutic and Vaccine Approaches Against Respiratory Pathogens
por: Calzas, Cynthia, et al.
Publicado: (2019)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Serological Protection 5–6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes
por: Idoko, Olubukola T., et al.
Publicado: (2020)

Development of a dual vaccine against East Coast fever and lumpy skin disease
por: Whittle, Leah, et al.
Publicado: (2023)

Vaccination against Q fever for biodefense and public health indications
por: Ruiz, Sara, et al.
Publicado: (2014)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
por: Lee, Jisun, et al.
Publicado: (2023)

Can reactogenicity predict immunogenicity after COVID-19 vaccination?
por: Hwang, Young Hoon, et al.
Publicado: (2021)

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians
por: Majumder, Md. Anwarul Azim, et al.
Publicado: (2022)

Editorial: New-generation vaccines and novel vaccinal strategies against infectious diseases of livestock, wild and companion animals
por: Pickering, Brad, et al.
Publicado: (2023)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components
por: Hernandez-Davies, Jenny E., et al.
Publicado: (2021)

Concomitant administration of COVD-19 vaccines with 'flu vaccines: acceptable reactogenicity profiles
Publicado: (2021)

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study
por: Iacono, Salvatore, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5d0o9c2uhgum4vqub6g6tbibep